KLRK1 and acute myeloid leukemia: After screening different agents and conditions, we established that NKG2D-ligand expression could be consistently increased in low-level expressing AML cell lines and in primary AML blasts after pretreatment with the HDAC inhibitor valproate and that this strategy significantly enhanced NKG2D-CAR anti-tumor responses against AML.